(Updated with corrected FDA approval decision date for Avanir Pharmaceuticals, which is Oct. 30, not Oct. 27, as previously reported.)

BOSTON (TheStreet) -- News of a drug's approval or rejection from the U.S. Food and Drug Administration can rock or kill a biotech stock's price. This FDA regulatory calendar is an update to the FDA approval calendar posted on April 7 and includes information on four new stocks with approval decision dates scheduled through the end of October. The 14 stocks are listed in chronological order, starting with the earliest FDA approval decision date.

Questcor Pharmaceuticals ( QCOR)

Drug/indication: Acthar for infantile spasms

Approval decision date: June 11

An FDA advisory panel said Acthar was safe and effective as a treatment for infant spasms at a meeting on May 6.

Glaxo's Radical Heart Drug (Forbes)

If you liked this article you might like

Link: I'm a Buyer of Bristol Myers in Low $30s

Eli Lilly, Verastem and the Defenders of Shareholder Value

Obamacare vs. the Stock Market

Stocks Finish Mixed; Nasdaq Extends Rally

Stephanie Link's Can Kickers -- Notes on Bristol-Myers Squibb